INTEGRIS Nazih Zuhdi Transplant Institute

Clinical Trials

If you have a potential patient, please call Kristin Mund, Clinical Research Manager at 405-713-4413.

Lung

  • NCT02630316 RIN-PH-201: “A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension Due to Parenchymal Lung Disease”
  • NCT02633293 RIN-PH-202: “An Open-Label Extension Study of Inhaled Treprostinil in Subjects with Pulmonary Hypertension Due to Parenchymal Lung Disease”
  • NCT03078907 AC-065A404 TRACE: “A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient's Self-reported Symptoms and Their Impacts”
  • NCT03045029 TDE-PH-401 ADAPT: “ADAPT - A Patient Registry of the Real-world Use of Orenitram®”
  • NCT02126943 AC-055-503 OPUS: “US-based, Observational, Drug Registry of Opsumit® (Macitentan) New Users in Clinical Practice”
  • H060002 03-0127: Spiration (IBV) Valve System (HDE/HUD) (Spiration, Inc.)

Kidney

  • NCT02547220 SHP616-302: “A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients”
  • NCT02921789 7163-CL-3201: “A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients”

Liver

  • NCT02548351 747-303 REGENERATE: “A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis”
  • NCT02770716 MNK19013058 The CONFIRM Study: “A Multi-Center, Randomized, Placebo Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects With Hepatorenal Syndrome Type 1 (The CONFIRM Study)”

Critical Care

  • NCT03384875 2017-001 REFRESH II Trial: “CytoSorb® Reduction of FREe Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery (REFRESH II Trial)”

INTEGRIS Advanced Cardiac Care

  • NCT02892955 MOMENTUM 3 CAP: “MOMENTUM 3 CAP Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy with HeartMate 3™ Continued Access Protocol”
  • NCT02232659: “SynCardia 70cc Temporary Total Artificial Heart (TAH-t) for Destination Therapy (DT)”
  • NCT02459054: “SynCardia 50cc Temporary Total Artificial Heart (TAH-t) as a Bridge to Transplant
  • NCT02554903 AC-055-205 SOPRANO: “A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Macitentan in Patients with Pulmonary Hypertension after Left Ventricular Assist Device Implantation”
  • NCT02861534 1242-001 VICTORIA: “A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)”
  • NCT02816736 HFN-LIFE: “EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)”
  • NCT03387813 CIP-10170 GUIDE-HF: “Hemodynamic-GUIDEd Management of Heart Failure”
  • NCT02030418 DC-02374: “Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker”